Physician profile
Emily Drury
NPI 1285124891
$2,404.10
in general payments reported to CMS, 2019-2025
14 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $336 · 2023: $488 · 2024: $700 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $841.61 | 2021-2025 | Nucala |
| Genzyme Corporation | $315.56 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $310.19 | 2024-2025 | Voquezna |
| Optinose US, INC. | $178.08 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $174.58 | 2024-2025 | Dupixent |
| Integra Lifesciences Corporation | $157.37 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Inspire Medical Systems, INC. | $129.45 | 2024 | Inspire |
| Aerin Medical INC. | $108.80 | 2022 | |
| Neurent Medical Limited | $48.71 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Hikma Pharmaceuticals USA | $47.26 | 2024-2025 | Ryaltris |
| Medtronic, INC. | $45.26 | 2021-2024 | Propel |
| Paratek Pharmaceuticals, INC. | $17.71 | 2025 | Xhance |
| Olympus America INC. | $15.68 | 2022 | |
| Hologic Sales and Service, LLC | $13.84 | 2024 | Coolseal Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Drury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.